Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19/BCMA CAR-T in Relapsed/Refractory Multiple Myeloma
NCT03706547Phase 1Unknown
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR-T cells in multiple myeloma (MM). Primary endpoint: Occurrence of study related adverse effects at 6 months. Status: unknown.
02
Drugs
anti-CD19/BCMA CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03706547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706547.